Report of the NIH Panel to Define Principles of Therapy of HIV Infection
REFERENCES
1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency
virus type 1 infection. Nature 1995;373:117-22.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M.
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
Nature 1995;373:123-6.
3. Embretson J, Zupancic M, Ribas J, et al. Massive covert infection
of helper T lymphocytes and macrophages by HIV during the incubation period
of AIDS. Nature 1993;362:359-62.
4. Pantaleo G, Graziosi C, Demarest J, et al. HIV infection is active
and progressive in lymphoid tissue during the clinically latent stage of
disease. Nature 1993;362:355-8.
5. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1
RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;
122:573-9.
6. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels
and time to development of AIDS in the Multicenter Hemophilia Cohort Study.
JAMA 1996;276:105-10.
7. Jurriaans S, van Gemen B, Weverling GJ, et al. The natural history
of HIV-1 infection: virus load and virus phenotype independent determinants
of clinical course. Virology 1994;204:223- 33.
8. Saksela K, Stevens CE, Rubenstein P, Taylor PE, Baltimore D. HIV-1
messenger RNA in peripheral blood mononucler cells as an early marker of
risk for progression to AIDS. Ann Intern Med 1995;123:641-8.
9. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1
RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl
J Med 1996;334:426-31.
10. O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1
RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum
Retrovirol 1998 (in press).
11. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate,
and late stages of HIV infection. JAMA 1996;275:1329-34.
12. Haynes BF, Panteleo G, Fauci AS. Toward an understanding of the
correlates of protective immunity to HIV infection. Science 1996;271:324-8.
13. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic
and immunologic markers to clinical outcomes after nucleoside therapy in
HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New
Eng J Med 1996;335:1091-8.
14. Dickover RE, Dillon M, Gillette SG, et al. Rapid increases in load
of human immunodeficiency virus correlate with early disease progression
and loss of CD4 cells in vertically infected infants. J Infect Dis 1994;170:1279-84.
15. McIntosh K, Shevitz A, Zaknun D, et al. Age- and time-related changes
in extracellular viral load in children vertically infected by human immunodeficiency
virus. Pediatr Infect Dis J 1996;15:1087-91.
16. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between
serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte
percent, and long-term mortality risk in HIV-1-infected children. J Infect
Dis 1997;175:1029-38.
17. Dickover RE, Dillon M, Leung K-M, et al. Early prognostic indicators
in primary perinatal HIV-1 infection: importance of viral RNA and the timing
of transmission on long term outcome. J Infect Dis 1998 (in press).
18. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression
in infants infected with human immunodeficiency virus type 1. New Engl
J Med 1997;336:1337-42. 19. Saag MS, Holodniy M, Kuritzkes DR,
et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-9.
20. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics
in vivo: virion clearance rate, infected cell life-span, and viral generation
time. Science 1996;271:1582-6.
21. Coffin JM. HIV population dynamics in vivo: implications for genetic
variation, pathogenesis, and therapy. Science 1995;267:483-9.
22. Raboud JM, Montaner JSG, Rae S, Conway B, Singer J, Schechter MT.
Issues in the design of trials of therapies for subjects with human immunodeficiency
virus infection that use plasma RNA level as an outcome. J Infect Dis 1997;175:576-82.
23. Kempf D, Molla A, Sun E, Danner S, Boucher C, Leonard J. The duration
of viral suppression is predicted by viral load during protease inhibitor
therapy [Abstract 603]. In: Programs and abstracts of the 4th Conference
on Retroviruses and Opportunistic Infections. Washington DC, January 22-26,
1997.
24. DeGruttola V, for the ACTG Cross Protocol Study Group. Prognostic
value of CD4 counts and plasma HIV RNA: an ACTG cross protocol analysis.
In: Proceedings of the Public Meeting of 2. Ho DD, Neumann AU, Perelson
AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and
CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
25. Palumbo PE, Raskino C, Fiscus S, et al. Correlation of HIV plasma
RNA levels with clinical outcome in a large pediatric trial (ACTG 152)
[Abstract LB14]. In: Program and abstracts of the 4th Conference on Retroviruses
and Opportunistic Infections. Washington DC, January 22-26, 1997.
26. Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration
for prediction of clinical course of human immunodeficiency virus disease:
a review. J Infect Dis 1992;165:352-63.
27. Mellors, JW, Muñoz A, Giorgi JV, et al. Plasma viral load
and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern
Med 1997;126:946-54.
28. USPHS/IDSA Prevention of Opportunistic Infections Working Group:
1997 USPHS/IDSA guidelines for the prevention of opportunistic infections
in persons infected with human immunodeficiency virus. MMWR 1997;46 (No.
RR-12).
29. El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management
of early HIV infection. Clinical practice guideline no. 7. AHCPR publication
no. 94-0572. Rockville, MD: Agency for Health Care Policy and
Research, Public Health Service, US Department of Health and Human Services,
January 1994.
30. CDC. 1995 Revised guidelines for prophylaxis against Pneumocystis
carinii pneumonia for children infected with or perinatally exposed to
human immunodeficiency virus. MMWR 1995;44(No. RR-4).
31. Schacker T, Hughes J, Shea T, Corey L. Viral load in acute and very
early HIV infection does not correlate with disease progression [Abstract
475]. In: Program and abstracts of the 4th Conference on Retroviruses and
Opportunistic Infections. Washington DC, January 22-26, 1997.
32. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus
replication after vaccination of HIV-1 infected individuals. J Exp Med
1995;182:1727-37.
33. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization
with a common recall antigen on viral expression in patients infected with
human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.
34. Brichacek B, Swindells S, Janoff EN, Pirrucello S, Stevenson M.
Increased plasma human immunodeficiency virus type 1 burden following antigenic
challenge with pneumococcal vaccine. J Infect Dis 1996;174:1191-9.
35. Raboud JM, Montaner JSG, Conway B, et al. Variation in plasma RNA
levels, CD4 cell counts, and p24 antigen levels in clinically stable men
with human immunodeficiency virus infection. J Infect Dis 1996;174:191-4.
36. Deeks SG, Coleman RL, White R, et al. Variance of plasma human immunodeficiency
virus type 1 RNA levels measured by branched DNA within and between days.
J Infect Dis 1997;176:514-7.
37. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of
HIV-1-infected compartments during combination therapy. Nature 1997;387:188-91.
38. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two
nucleoside analogues plus indinavir in persons with human immunodeficiency
virus infection and CD4 cell counts of 200 per cubic millimeter or less.
N Engl J Med 1997; 337:725-33.
39. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir,
zidovudine, and lamivudine in adults with human immunodeficiency virus
infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
40. Montaner J, Wainberg M, INCAS study results. In: Proceedings of
the Public Meeting of the NIH Panel To Define Principles of Therapy of
HIV Infection, Nov. 13-14, 1996. Washington, DC: Office of AIDS
Research, NIH.
41. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification
of HIV-1 RNA in plasma using a branched DNA signal amplification assay.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:446-54.
42. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L,
Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency
virus type 1 RNA in plasma: application to acute retroviral infection.
J Clin Microbiol 1994;32:292-300.
43. Vandamme AM, Van Dooren S, Kok W, et al. Detection of HIV-1 RNA
in plasma and serum samples using the NASBA amplification system compared
to RNA-PCR. J Virol Methods 1995;52:121-32.
44. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a
quality assurance program for quantitation of human immunodeficiency virus
type 1 RNA in plasma by the AIDS Clinical Trials Group Virology Laboratories.
J Clin Microbiol 1996;34:2695-701.
45. Schuurman R, Descamps D, Jan Weverling G, et al. Multicenter comparison
of three commercial methods for quantification of human immunodeficiency
virus type 1 RNA in plasma. J Clin Microbiol 1996;34:3016-22.
46. Revets H, Marissens D, de Wit S, et al. Comparative evaluation of
NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay,
three methods for quantification of human immunodeficiency virus type 1
RNA in plasma. J Clin Microbiol 1996;34:1058-64.
47. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue
reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-8.
48. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in
lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science
1997;276:960-4.
49. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent
HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-4.
50. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir
for HIV-1 in patients on highly active antiretroviral therapy. Science
1997;278:1295-8.
51. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333:450-1.
52. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant
transmission of human immunodeficiency virus type 1 with zidovudine treatment.
N Engl J Med 1994;331:1173-80.
53. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load,
zidovudine treatment, and the risk of transmission of human immunodeficiency
virus type 1 from mother to infant. New Engl J Med 1996;335:1621-9.
54. CDC. Public Health Service Task Force recommendations for the use
of antiretroviral drugs in pregnant women infected with HIV-1 for maternal
health and for reducing perinatal HIV-1 transmission in the United States.
MMWR 1998;47(RR-2).
55. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine,
and didanosine compared with zidovudine and didanosine in patients with
HIV-1 infection. Ann Intern Med 1996;124:1019-30.
56. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine
or lamivudine plus lovirride to zidovudine-containing regimens for patients
with HIV-1 infection: the CAESAR trail. Lancet 1997;349:1413-21.
57. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of
lamivudine-zidovudine combination therapy in zidovudine-experienced patients.
JAMA 1996;276:111-7.
58. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine
combination therapy in antiretroviral-naive patients. JAMA 1996;276:118-25.
59. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine,
zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells
per cubic millimeter. New Engl J Med 1995;333:1662-9.
60. Van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety
and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly
symptomatic human immunodeficiency virus infection: a phase I/II study.
J Infect Dis 1995;171:1166-71.
61. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant
human immunodeficiency virus: kinetics of replication and estimated prevalence
in untreated patients. J Virol 1996;70:7894-9.
62. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors:
a review for clinicians. JAMA 1997;277:145-53.
63. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease
inhibitors. Arch Intern Med 1997;157:951-9.
64. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women.
Am J Obstet Gynecol 1997;176:478-89.
65. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and
vertical transmission of infection: the Ariel Project for the prevention
of HIV transmission from mother to infant. Nat Med 1997;3:549-52.
66. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment
with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency
virus type 1 infection. New Engl J Med 1997;336:1343-9.
67. Kinloch-De Loës S, Hirschel BJ, Hoen B, et al. A controlled
trial of zidovudine in primary human immunodeficiency virus infection.
N Engl J Med 1995;333:408-13.
68. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes
O. Effects of a combination of zidovudine, didanosine, and lamivudine on
primary human immunodeficiency virus type 1 infection. J Infect Dis 1997;175:1051-5.
69. Hoen B, Harzic M, Fleury H, et al. ANRS053 trial of zidovudine (ZDV),
lamivudine (3TC), and ritonavir combination in patients with symptomatic
primary HIV-1 infection: preliminary results [Abstract 232]. In: Program
and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
Washington, DC, Jan. 22-26, 1997.
70. Tamalet C, Martin IP, Lafeuillade A. Viral load and genotypic resistance
pattern in HIV-1 infected patients treated by a triple combination therapy
including nucleoside and protease inhibitors (NIS and PIS) initiated at
primary infection (PHI) [Abstract 592]. In: Program and abstracts of the
4th Conference on Retroviruses and Opportunistic Infections. Washington,
DC, January 22-26, 1997.
71. Perrin L, Markowitz M, Calandra G, Chung M, and the MRL Acute HIV
Infection Study Group. An open treatment study of acute HIV infection with
zidovudine, lamivudine and indinavir sulfate [Abstract 238]. In: Program
and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
Washington, DC, January 22-26, 1997.
72. Markowitz M, Cao Y, Vesanan M, et at. Recent HIV infection treated
with AZT, 3TC, and a potent protease inhibitor [Abstract LB8]. In: Program
and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
Washington, DC, January 22-26, 1997.
73. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1
specific CD4+T cell responses associated with control of viremia. Science
1997;278:1447-50.
74. Weiss RA. HIV receptors and the pathogenesis of AIDS. Science 1996;272:1885-6.
75. Moore, JP, Trkola A, Dragic T. Coreceptors for HIV-1 entry. Curr
Opin Immunol 1997;9:551-62.
76. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and
CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med
1995;332:143-9.
77. Darby SC, Weart DW, Giangrande PLF, Spooner RJD, Rizza CR. Importance
of age at infection with HIV-1 for survival and development of AIDS in
UK haemophilia population. Lancet 1996;347:1573-9.
78. Koot M, B van't Wout AB, Kootstra NA, EY de Goede R, Tersmette M,
Schuitemaker H. Relation between changes in cellular load, evaluation of
viral phenotype, and the clonal composition of virus populations in the
course of human immunodeficiency virus type infection. J Infect Dis 1996;173:349-54.
79. Margolick JB, Muñoz A, Donnenberg AD, et al. Failure of T-cell
homeostasis preceding AIDS in HIV-1 infection. Nat Med 1995;7:674-80.
80. Shearer G, Clerici M. Early T-helper cell defects in HIV infection.
AIDS 1991;5:245-53.
81. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci
AS. Preferential infection of CD4+ memory T cells by human immunodeficiency
virus type 1: evidence for a role in selective T-cell functional defects
observed in infected individuals. Proc Natl Acad Sci USA 1990;87:6058-62.
82. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes
in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire
that are not immediately restored by antiviral or immune-based therapies.
Nat Med 1997;3:533-40.
83. Piatak M Jr, Yang LC, Luk KC, et al. Viral dynamics in primary HIV-1
infection (letter). Lancet 1993:341:1099.
84. Tindall B, Cooper DA. Primary HIV infection: host responses and
intervention strategies. AIDS 1991;5:1-14.
85. Kinloch de Loës S, de Saussure P, Saurat JH, Stalder H, Hirschel
B, Perrin LH. Symptomatic primary infection due to human immunodeficiency
virus type 1: review of 31 cases. Clin Infect Dis 1993;17:59-65.
86. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and
epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-64.
87. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma
during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
88. Cao Y, Ho DD, Todd J, Kokka R, et al. Clinical evaluation of branched
DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS
Res Hum Retroviruses 1995;11:353-61.
89. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency
virus type 1 than that predicted from the fidelity of purified reverse
transcriptase. J Virol 1995;69:5087-94.
90. Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid
emergence of HIV-1 dually resistant mutants under selective drug pressure.
Proc Natl Acad Sci USA 1996;93:6106- 11.
91. de Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics
and outgrowth of virus containing a single K70R amino acid change in reverse
transcriptase are responsible for the loss of human immunodeficiency virus
type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA 1996;93:5501-6.
92. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed
in HIV-1 clade B protease gene using high-density oligonucleotide arrays.
Nat Med 1996;2:753-9.
93. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human
immunodeficiency virus type 1 RNA load and appearance of drug-resistant
virus populations in persons treated with lamivudine (3TC). J Infect Dis
1995;171:1411-9.
94. Pluda JM, Cooley TP, Montaner JSG, et al. A phase I/II Study of
2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency
virus infection. J Infect Dis 1995;171:1438-47.
95. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations
of human immunodeficiency virus type 1 selected during therapy. J Virol
1994;68:1660-6.
96. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1
variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
97. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in
vivo viral resistance to indinavir, a human immunodeficiency virus type
1 protease inhibitor. J Virol 1996;70:8270-6.
98. Imrie A, Beveridge A, Genn W, et al. Transmission of human immunodeficiency
type 1 resistant to nevirapine and zidovudine. J Infect Dis 1997;175:1502-6.
99. Holodiny M, Mole L, Margolis D, et al. Determination of human immunodeficiency
virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance
and viral load during zidovudine-didanosine combination therapy. J Virol
1995;69:3510-6.
100. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations
in HIV protease confers resistance in ritonavir. Nature Med 1996;2:760-6.
101. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the
immune response of human immunodeficiency virus (HIV)-infected subjects
treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis
1996;173:321-9.
102. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis
after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
103. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect
of combination antiretroviral therapy on cytomegalovirus retinitis (letter).
JAMA 1997;277:1519-20.
104. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum
contagiosum in a human immunodeficiency virus-infected patient after institution
of antiretroviral therapy with ritonavir. Clin Infect Dis 1997;24:1023-5.
105. Benhamou Y, Bochet MV, Carriere J, et al. Effects of triple antiretroviral
therapies including a HIV protease inhibitor on chronic intestinal cryptosporidiosis
and microsporidiosis in HIV-infected patients [Abstract 357]. In: Program
and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
Washington, DC, January 22-26, 1997.
106. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis
B infection in HIV-infected patient on protease inhibitor [Letter]. Lancet
1997;349:995-6.
107. Phillips P, Zala C, Rouleau D, Montaner JSG. Mycobacterial lymphadenitis:
can highly active antiretroviral therapy (HAART) unmask subclinical infection?
[Abstract 351]. In: Program and abstracts of the 4th Conference on Retroviruses
and Opportunistic Infections. Washington, DC, January 22-26,
1997.
Go to the NIH Report Menu
Go to the HIVpositive.us Main Menu